Home › Liver Diseases › Ohio › Cincinnati
Liver Diseases clinical trials in Cincinnati, OH
4 studies for Liver Diseases are looking for participants at sites in and around Cincinnati (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
RecruitingPhase 3
- 89bio Clinical Study Site, Cincinnati
- 89bio Clinical Study Site, Liberty Township · 20 mi away
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
RecruitingPhase 3
- 89bio Clinical Study Site, Liberty Township · 20 mi away
Primary Sclerosing Cholangitis in Children
RecruitingObservational study
- Cincinnati Children's Hospital Medical, Cincinnati
A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
RecruitingPhase 2
- Oncology Hematology Care Clinical Trials, LLC, Cincinnati
About Liver Diseases
Get the facts about liver diseases, such as hepatitis, cancer, and cirrhosis. Know your risk and what you can do to prevent liver problems.
More about Liver Diseases on MedlinePlus
Liver Diseases trials in other cities
- Houston, TX10 studies
- Chicago, IL9 studies
- Washington, DC8 studies
- Los Angeles, CA7 studies
- Atlanta, GA7 studies
- Philadelphia, PA6 studies
- Richmond, VA6 studies
- New York City, NY6 studies
- San Antonio, TX6 studies
- Durham, NC5 studies
- Ann Arbor, MI5 studies
- Dallas, TX5 studies
Other studies in Cincinnati
- Non-Small Cell Lung Cancer31 studies
- Cancer (all types)26 studies
- Breast Cancer24 studies
- Heart Failure22 studies
- Metastatic Cancer21 studies
- Colorectal Cancer20 studies
- Obesity20 studies
- Acute Myeloid Leukemia20 studies
- Prostate Cancer19 studies
- Ovarian Cancer18 studies
- Lung Cancer18 studies
- Multiple Myeloma17 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.